News
VTVT
21.20
+0.90%
0.19
Stocks to Watch: vTv Therapeutics, BJ's Restaurants, Warner Bros. Discovery
Dow Jones · 2h ago
BUZZ-vTv Therapeutics falls after FDA places clinical hold on its diabetes study
VTv Therapeutics falls after FDA places clinical hold on its diabetes study. Shares of drug developer fall 39% to $12.95 after the bell. Company says FDA has placed a hold on study testing its experimental treatment for type 1 diabetes. Stock has risen 84.4% YTD.
Reuters · 3h ago
vTv Therapeutics Shares Tumble After FDA Pauses Diabetes-Treatment Study >VTVT
Dow Jones · 3h ago
VTv Therapeutics's Cadisegliatin Program For Type 1 Diabetes Placed On Clinical Hold, Stock Tanks
NASDAQ · 3h ago
FDA places clinical hold on vTv's cadisegliatin clinical program
FDA places clinical hold on vTv's cadisegliatin clinical program for the treatment of type 1 diabetes. The company says a chromatographic signal could not be resolved by mass spectroscopy. The hold includes the CATT1 Phase 3 study of the product.
Seeking Alpha · 5h ago
VTv Therapeutics' Cadisegliatin Clinical Program Put On Hold By FDA
Dow Jones · 5h ago
vTv Therapeutics Announces FDA Has Placed A Clinical Hold On The Cadisegliatin Clinical Program Which Includes The Ongoing CATT1 Phase 3 Trial In Type 1 Diabetes
VTv Therapeutics says FDA has placed a clinical hold on its cadisegliatin clinical program in type 1 diabetes. The company's lead program includes the ongoing CATT1 Phase 3 trial in the disease. Cadise gliatin is an oral, liver selective, glucokinase activator.
Benzinga · 5h ago
VTV THERAPEUTICS INC - CLINICAL HOLD INCLUDES ONGOING CATT1 PHASE 3 TRIAL
Reuters · 5h ago
VTV THERAPEUTICS INC: AGENCY REQUIRES A SINGLE IN VITRO STUDY TO CHARACTERIZE SIGNAL BEFORE CADISEGLIATIN PROGRAM CAN RESUME
Reuters · 5h ago
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
The FDA has placed a clinical hold on the cadisegliatin clinical program in type 1 diabetes. VTv Therapeutics Inc. Is a late stage biopharmaceutical company with a lead program in diabetes. The company's ongoing CATT1 Phase 3 trial in type one diabetes is well-tolerated.
Barchart · 10h ago
Weekly Report: what happened at VTVT last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at VTVT last week (0708-0712)?
Weekly Report · 07/15 12:07
Weekly Report: what happened at VTVT last week (0701-0705)?
Weekly Report · 07/08 12:09
VTV THERAPEUTICS: IN 2ND AMENDMENT, ON NEWSOARA PAYMENT OF $20 MLN UPFRONT FEE, ORIGINAL LICENSE TO BE EXPANDED TO GLOBAL LICENSE
Reuters · 07/02 20:43
VTV THERAPEUTICS: GOT INTO SECOND AMENDMENT TO LICENSE AGREEMENT WITH NEWSOARA BIOPHARMA CO
Reuters · 07/02 20:43
Weekly Report: what happened at VTVT last week (0624-0628)?
Weekly Report · 07/01 12:10
Vtv Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 06/28 00:36
vTv Therapeutics Screens First Patient In CATT1 Pivotal Trial Evaluating Cadisegliatin For Type 1 Diabetes
Benzinga · 06/24 20:05
VTV THERAPEUTICS ANNOUNCES SCREENING OF FIRST PATIENT IN CATT1 PIVOTAL TRIAL EVALUATING CADISEGLIATIN FOR TYPE 1 DIABETES
Reuters · 06/24 20:05
Weekly Report: what happened at VTVT last week (0617-0621)?
Weekly Report · 06/24 12:21
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.